PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30709866-2	2019	The beta 2-adrenergic receptor (beta 2AR) agonist formoterol accelerates the recovery of renal function in mice after ischemia-reperfusion injury (IRI) with associated rescue of mitochondrial proteins; however, the cell type responsible for this recovery remains unknown.	Formoterol Fumarate	50-60	adenosine A2a receptor	Mus musculus	32-40	
34029162-6	2021	In this study we demonstrate that injection of formoterol, a highly selective beta2-AR agonist, to mice acutely results in hepatic TG accumulation.	Formoterol Fumarate	47-57	adenosine A2a receptor	Mus musculus	78-86	
34029162-8	2021	Our results suggest that beta2-AR activation by formoterol leads to increased hepatic TG synthesis and de novo lipogenesis, increased but incomplete beta-oxidation of fatty acids with accumulation of potentially toxic long-chain acylcarnitine intermediates, and reduced TG secretion-all previously invoked as contributors to fatty liver disease.	Formoterol Fumarate	48-58	adenosine A2a receptor	Mus musculus	25-33	
34029162-9	2021	Experiments are ongoing to determine whether sustained activation of hepatic beta2-AR signaling by formoterol might be utilized to model fatty liver changes occurring in hyperadrenergic states of obesity and aging, and thereby identify novel molecular targets for the prevention or treatment of NAFLD.	Formoterol Fumarate	99-109	adenosine A2a receptor	Mus musculus	77-85	
30709866-10	2019	Formoterol accelerates the recovery of renal function after AKI by activating proximal tubule beta 2AR to induce mitochondrial biogenesis and demonstrates the overall requirement of RPTCs in renal recovery.	Formoterol Fumarate	0-10	adenosine A2a receptor	Mus musculus	94-102